Gene testing may not be accurate
Nov 7, 2011
A recent study published in the Journal of Clinical Oncology found that Genomic Health's Oncotype DX was giving false negatives for the HER2 gene, which is a gene that can heighten the risk of individuals being diagnosed with breast cancer.
"None of us would request Oncotype for the sole purpose of getting HER2," said Dr. Lori J. Goldstein. "We're usually ordering it for other reasons and, as part of that test, we get HER2."
However, it has been used as a reliable source and now many are concerned. As a result, the researchers advise those who have had the test to ensure that their hormone-receptor analyses were conducted by FDA-approved methods.
However, Genomic Health disagreed with the findings and explained that they think it was completely one-sided.
According to the American Cancer Society, one in eight women in the U.S. will be diagnosed with breast cancer at some point during her lifetime. It is not only the second most common form of cancer among women behind skin cancer, but it is also the second leading cause of cancer-related death among women, following only lung cancer.